| Description | DNAH8 Human Pre-designed siRNA Set A contains three designed siRNAs for DNAH8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DNAH8 siRNA-1: 5 nmol (HPLC) DNAH8 siRNA-2: 5 nmol (HPLC) DNAH8 siRNA-3: 5 nmol (HPLC) siRNA Negative Control:DNAH8 Human Pre-designed siRNA Set A contains three designed siRNAs for DNAH8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DNAH8 siRNA-1: 5 nmol (HPLC) DNAH8 siRNA-2: 5 nmol (HPLC) DNAH8 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Source: Microorganism Isoelectric point: 6.5 Michaelis constant: 9.2×10^-3 M (D-Glucose); 8.6×10^-3 M (NAD) Optimum pH: 9.0~9.5 Fig. 1Optimum temperature: 55℃ Fig. 3pH Stability: 6.0-10.0 (25℃, 24hr) Fig. 2Thermal stability: <50℃ (pH 8.0, Source: Microorganism Isoelectric point: 6.5 Michaelis constant: 9.2×10^-3 M (D-Glucose); 8.6×10^-3 M (NAD) Optimum pH: 9.0~9.5 Fig. 1Optimum temperature: 55℃ Fig. 3pH Stability: 6.0-10.0 (25℃, 24hr) Fig. 2Thermal stability: <50℃ (pH 8.0, 30min) Fig. 4Inhibitors: NEM,SDS Effect of various chemicals: Table 1Reaction:... Read More | Lipoprotein Lipase Activator is a cell-permeable benzylphosphonate derivative that selectively induces lipoprotein lipase (LPL) mRNA and protein levels, but does not exhibit PPARα or PPARγ agonistic activities. Lipoprotein Lipase Activator lowers serum lipid levels and plasma triglyceridesLipoprotein Lipase Activator is a cell-permeable benzylphosphonate derivative that selectively induces lipoprotein lipase (LPL) mRNA and protein levels, but does not exhibit PPARα or PPARγ agonistic activities. Lipoprotein Lipase Activator lowers serum lipid levels and plasma triglycerides with concomitant elevation in high-density lipoprotein cholesterol (HDL-C) in animal models. Lipoprotein Lipase Activator also induces fatty acid oxidation related enzymes, lowers free fatty acids (FFA), and minimizes fat accumulation. Also reported to suppress the plasma levels of TNF-a and COX-2 and displays anti-tumor properties... Read More | Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description:HSPD1, also known as HSP60, is a member of the chaperonin family. HSPD1 may function as a signaling molecule in the innate immune system. This protein is essential for the folding and assembly of newly Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description:HSPD1, also known as HSP60, is a member of the chaperonin family. HSPD1 may function as a signaling molecule in the innate immune system. This protein is essential for the folding and assembly of newly imported proteins in the mitochondria. It may also prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under stress conditions in the mitochondrial matrix. HSPD1 gene is adjacent to a related family member and the region between the 2 genes functions as a bidirectional promoter. Several pseudogenes have been associated with this gene. Mutations associated with this gene cause autosomal recessive spastic paraplegia 13. Defects in HSPD1 are a cause of spastic paraplegia autosomal dominant type 13 (SPG13). Spastic paraplegia is a degenerative spinal cord disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Defects in HSPD1 are the cause of leukodystrophy hypomyelinating type 4 (HLD4); also called mitochondrial HSP60 chaperonopathy or MitCHAP-60 disease. HLD4 is a severe autosomal recessive hypomyelinating leukodystrophy. HSPD1 is clinically characterized by infantile-onset rotary nystagmus, progressive spastic paraplegia, neurologic regression, motor impairment, profound mental retardation. Death usually occurs within the first two decades of life... Read More | Inquire |